| Current Price | $65.48 | Mkt Cap | $82.1B |
|---|---|---|---|
| Open | $65.75 | P/E Ratio | 65.04 |
| Prev. Close | $65.48 | Div. (Yield) | $2.72 (4.2%) |
| Daily Range | $65.08 - $66.92 | Volume | 5,115 |
| 52-Wk Range | $56.56 - $85.97 | Avg. Daily Vol. | 9,766,826 |
A biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need.
| Current Price | $65.48 | Mkt Cap | $82.1B |
|---|---|---|---|
| Open | $65.75 | P/E Ratio | 65.04 |
| Prev. Close | $65.48 | Div. (Yield) | $2.72 (4.2%) |
| Daily Range | $65.08 - $66.92 | Volume | 5,115 |
| 52-Wk Range | $56.56 - $85.97 | Avg. Daily Vol. | 9,766,826 |
The best Bull and Bear pitches based on recency and number of recommendations.
This company has proved that it can cure diseases. It has over $30B in cash. Good mgmt. Good yield. As of today at has a P/E of 7. If this company was not here tomorrow, people would notice.
I have a real hard time imagining that Gilead will have sold enough Remdesivir to make this stock a market performer much less a market *beater.* I do continue to own shares in my real portfolio though, so I'm happy to be proven wrong. Underperform.
Read the most recent pitches from players about GILD.
Recs
Dividends500
(78.22)
Submitted: 12/31/2020 11:37:12 PM :
Start Price:
$58.67
NASDAQ:GILD Score:
+11.85
Dividends500 tracks the healthiest dividends in the S&P 500.
To qualify for the portfolio, the company must meet three simple requirements:
- Member of the S&P 500
- Payout ratio below 50%
- Dividend growth year over year
Recs
dusand
(92.03)
Submitted: 12/11/2020 1:46:33 PM :
Start Price:
$59.98
NASDAQ:GILD Score:
+6.68
Looks cheap. This company has several projects with positive surprise potential. Also, the stock price fell to a level where it becomes a value pick.
Recs
TMFjbonefish
(60.21)
Submitted: 11/23/2020 12:46:07 PM :
Start Price:
$58.89
NASDAQ:GILD Score:
-6.15
More data on Remdesivir likely to show it's not very effective; A new administration will undo FDA approval if liver and kidney side effects persist. Increasingly desperate acquisitions at extreme valuations will be hard to generate a return. Finally, the US government is going to take profits or patents related to HIV and hepatitis -- I don't see a way around that severely limiting the company's profit moving forward.
Find the members with the highest scoring picks in GILD.
BrianMotleyFool (70.13) Score: +536.73
The Score Leader is the player with the highest score across all their picks in GILD.
|
Top Pick |
Member Name |
Member Rating |
Start Date |
Call |
Time Frame |
Start Price |
Stock Gain |
Index Gain |
Score | Commentary |
|---|---|---|---|---|---|---|---|---|---|---|
| WilliamCrook2003 | 71.49 |
|
|
5Y | $13.27 | +393.51% | +179.49% | +214.02 | 1 Comment | |
| UrineLuck73 | < 20 | 1/29/2007 |
|
NS | $13.27 | +393.51% | +179.49% | +214.02 | 0 Comment | |
| JSergeant | 73.39 | 7/3/2006 |
|
3Y | $12.57 | +421.13% | +213.01% | +208.12 | 0 Comment | |
| predragj | 40.31 | 1/30/2007 |
|
NS | $13.44 | +387.26% | +179.17% | +208.09 | 0 Comment | |
| mxdfool | < 20 | 12/15/2006 |
|
5Y | $13.50 | +385.04% | +178.21% | +206.83 | 0 Comment | |
| betsypurcell | < 20 | 1/24/2007 |
|
NS | $13.52 | +384.37% | +177.97% | +206.40 | 0 Comment | |
| rmarinchek | < 20 | 1/25/2007 |
|
3W | $13.62 | +380.74% | +176.28% | +204.46 | 0 Comment | |
| Redskins2k9 | < 20 | 1/25/2007 |
|
5Y | $13.62 | +380.74% | +176.28% | +204.46 | 0 Comment | |
| opveiby | 77.96 | 1/25/2007 |
|
5Y | $13.62 | +380.74% | +176.28% | +204.46 | 0 Comment | |
| jer8899 | 70.12 | 1/23/2007 |
|
NS | $13.59 | +381.79% | +178.00% | +203.79 | 0 Comment |
See what the Wall Street professionals think, according to their public statements and filings.
